InnoCan Pharma Corporation INNPF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 94.07% | -67.01% | 1,850.00% | -571.38% | -275.07% |
| Total Depreciation and Amortization | -44.44% | -20.00% | 100.00% | 22.22% | -10.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5,056.25% | -51.36% | -356.88% | 140.43% | -223.08% |
| Change in Net Operating Assets | -69.45% | -47.83% | 167.40% | 90.44% | 307.30% |
| Cash from Operations | -167.49% | -237.50% | -15.28% | 102.19% | 1.63% |
| Capital Expenditure | -800.00% | -- | -50.00% | 33.33% | 66.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -98.55% | -- | -- |
| Cash from Investing | -350.00% | -- | -107.69% | 33.33% | 33.33% |
| Total Debt Issued | -- | -29.69% | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | 50.00% | 20.00% |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | -100.00% | -- |
| Cash from Financing | 30.72% | -54.82% | -100.00% | -100.35% | 3,160.00% |
| Foreign Exchange rate Adjustments | -16.98% | -33.33% | 130.00% | -100.00% | 172.60% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -125.62% | -104.42% | -1,089.80% | 111.36% | 49.83% |